Ref : http://www.upmc.com/media/NewsReleases/2014/Pages/upci-scientists-detect-therapy-for-drug-resistant-cancer.aspx
Tuesday, February 18, 2014
Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer
Ref : http://www.upmc.com/media/NewsReleases/2014/Pages/upci-scientists-detect-therapy-for-drug-resistant-cancer.aspx
Sunday, February 2, 2014
Biotechdaily - Nilotinib Enhances Toxic Protein Removal from Parkinson's Disease Neurons
"No one has tried anything like this before," said senior author Dr. Charbel E-H Moussa, assistant professor of neuroscience at the Georgetown University Medical Center. "This drug, in very low doses, turns on the garbage disposal machinery inside neurons to clear toxic proteins from the cell. By clearing intracellular proteins, the drug prevents their accumulation in pathological inclusions called Lewy bodies and/or tangles, and also prevents amyloid secretion into the extracellular space between neurons, so proteins do not form toxic clumps or plaques in the brain."
"The doses used to treat CML are high enough that the drug pushes cells to chew up their own internal organelles, causing self-cannibalization and cell death," said Dr. Moussa. "We reasoned that small doses—for these mice, an equivalent to 1% of the dose used in humans—would turn on just enough autophagy in neurons that the cells would clear malfunctioning proteins, and nothing else. We successfully tested this for several diseases models that have an accumulation of intracellular protein. It gets rid of alpha-synuclein and tau in a number of movement disorders, such as Parkinson's disease as well as Lewy body dementia."
Tuesday, December 17, 2013
Peptide derived from cow's milk kills human stomach cancer cells in culture
Tuesday, December 10, 2013
Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Friday, November 22, 2013
New Cancer Targeting Technique to Improve Cancer Drugs
Wednesday, November 6, 2013
New drug candidate found for deadly fungal lung infections
Monday, July 22, 2013
New class of highly potent antimalarial compounds discovered
Torins are capable of killing the cultured blood stages of the human parasite, Plasmodium falciparum, the species which causes most malaria deaths and severe disease, and are equally potent against the liver stages of a model rodent parasite. A single dose of the compound Torin2 delivered at the beginning of the P. berghei liver stage is sufficient to eliminate infection in mice before any Plasmodium parasites reach the blood. "Given the alarming trend of resistance to our current antimalarial therapies, this is really an exciting finding," says Dr. Mota, the senior author of the study, "and we are already working to develop Torin molecules suitable for clinical trials of antimalarial activity in humans."
Tuesday, July 9, 2013
Smart anticancer 'nanofiber mesh'
Ref : http://onlinelibrary.wiley.com/doi/10.1002/adfm.201300746/abstract;jsessionid=A14E178EC5E6FC5D367A7C71FF0D30BC.d02t01
Smart anticancer 'nanofiber mesh'
Wednesday, June 19, 2013
Diabetes drug points the way to overcoming drug resistance in melanoma
Sunday, January 20, 2013
p53 activation suppresses malic enzyme expression and leads to senescence in pre-cancerous cells
"We uncovered an important regulatory mechanism for p53 as well as an effector mechanism for p53," Yang says.
Saturday, September 22, 2012
New drug candidate shows promise against cancer - MIT Media Relations
“I’ve long believed that there’s something special about platinum and its ability to treat cancer. Using new variants, we might have a chance of applying platinum to a broader range of cancer types, more successfully,” said Lippard. Lippard is senior author of a paper describing the new drug candidate, known as phenanthriplatin - which is cis-[Pt(NH3)2(phenanthridine)Cl]NO3.
Monday, June 11, 2012
Drug kills cancer cells by restoring faulty tumor suppressor
Restoring the function of mutant p53 with a drug has long been recognized as an attractive cancer therapeutic strategy," explains senior study author, Dr. Darren R. Carpizo, from The Cancer Institute of New Jersey. "However, it has proven difficult to find compounds that restore the lost function of a defective tumor-suppressor."
Monday, April 16, 2012
Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells
Friday, March 23, 2012
A New Approach to Faster Anticancer Drug Discovery
Tuesday, March 20, 2012
Antidepressant, TCP (Trabylcypromine) could help the workings of anticancer drug used in leukemia...
Friday, January 28, 2011
Discovery of a Biochemical Basis for Broccoli's Cancer-Fighting Ability
Saturday, November 6, 2010
Mouse study finds black raspberries can prevent colorectal cancer
We know that, The blackberries, as well as various other Rubus species with mounding or rambling growth habits, are often called brambles. However, this name is not used for those like the raspberry that grow as upright canes, or for trailing or prostrate species such as most dewberries, or various low-growing boreal, arctic, or alpine species. Black raspberries have been also reported to possess antioxidant, anti-cancer, anti-neurodegenerative and anti-inflammatory properties, now the researchers from UIC College of Medicine have looked at the fruit's ability to prevent colon cancer.
The researchers used two strains of mice, Apc1638 and Muc2, which each have a specific gene knocked out, causing the mice to develop either intestinal tumors (in the case of Apc1638) or colitis in the case of Muc2. Colitis is an inflammation of the large intestine that can contribute to the development of colorectal cancer.
Both mouse strains were randomized to be fed either a Western-style, high-risk diet (high in fat and low in calcium and vitamin D) or the same diet supplemented with 10 percent freeze-dried black raspberry powder for 12 weeks.
The researchers found that in both mouse strains the black raspberry-supplemented diet produced a broad range of protective effects in the intestine, colon and rectum and inhibited tumor formation.
In the Apc1638 mice, tumor incidence was reduced by 45 percent and the number of tumors by 60 percent. The researchers found that black raspberries inhibited tumor development by suppressing a protein, known as beta-catenin, which binds to the APC gene.
In the Muc2 mice, tumor incidence and the number of tumors were both reduced by 50 percent, and black raspberries inhibited tumor development by reducing chronic inflammation associated with colitis.
The researchers now hope to obtain funding to begin clinical trials in humans. Because black raspberries not only prevent cancer but also inflammation, they may also protect against other diseases, such as heart disease.
I read an article in the same lines, wherein the researchers attribute the colorectal anticancer activity due to the anthocyanins present
More...